论文部分内容阅读
目的观察普洛迪对缺血性卒中患者的临床疗效和安全性。方法23例缺血性卒中患者随机分为两组,在给予基础治疗的前提下,治疗组(11例)给予普洛迪静脉滴注,对照组(12例)给予复方丹参注射液静脉滴注,观察治疗前和治疗后20d后的神经功能缺失评分(NIH)和临床有效率。结果治疗组神经功能缺损评分(NIH)减少程度高于对照组(P<0.01)。治疗组显效率72.73%,总有效率90.91%;对照组显效率41.67%,总有效率58.33%,治疗组有效率显著高于对照组(P<0.01),两组均无明显相关的严重不良反应。结论普洛迪治疗缺血性卒中安全有效。
Objective To observe the clinical efficacy and safety of Prodil in patients with ischemic stroke. Methods Twenty-three patients with ischemic stroke were randomly divided into two groups. Under the premise of basic treatment, Prodi was given intravenously in the treatment group (11 cases) and intravenous infusion of compound Salvia injection in the control group (12 cases) The neurological deficit score (NIH) and clinical efficiency were observed before treatment and 20 days after treatment. Results The neurological deficit score (NIH) in treatment group decreased more than that in control group (P <0.01). The effective rate of the treatment group was 72.73% and the total effective rate was 90.91%. The effective rate of the control group was 41.67% and the total effective rate was 58.33%. The effective rate of the treatment group was significantly higher than that of the control group (P <0.01) reaction. Conclusion Prodil is safe and effective in treating ischemic stroke.